BioSpace News Archive

The GALACELA Phase 2 trial (NCT05856448) is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3667 in adults with active SLE.

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2023 financial results and provided a corporate update.

Daxor Corporation, the global leader in blood volume measurement technology, announces it filed Form N-CSR disclosing its schedule of portfolio holdings for the six-months ended June 30, 2023.

Illumina, Inc. announced that its executives will be speaking at the following investor conference.

LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at the upcoming 21st Annual Morgan Stanley Global Healthcare Conference, which will be hosted in New York City, NY.

LIB Therapeutics Inc., a clinical-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor medicines for patients at very high and high risk of cardiovascular disease (“CVD”) requiring additional reductions in LDL- cholesterol (“LDL-C” or “LDL”), in patients on maximally tolerated statins and other oral lipid lowering agents, announced the results of the LIBerate-HeFH trial.

Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced a substantial increase in the power and capabilities of RADR® focused on improving the drug development process for immune checkpoint inhibitors (ICIs).

Turn Biotechnologies co-founder Vittorio Sebastiano will share company data during a presentation on the potential of epigenetic reprogramming to increase human longevity during this week’s 10th Aging Research and Drug Discovery Meeting, the world’s largest longevity forum.

Biomerica Inc., a global biomedical company leading the way in innovative gastroenterology solutions, announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors.